JP2023502259A - 肺疾患の治療のためのｃｅｌａ－１阻害 - Google Patents

肺疾患の治療のためのｃｅｌａ－１阻害 Download PDF

Info

Publication number
JP2023502259A
JP2023502259A JP2022529298A JP2022529298A JP2023502259A JP 2023502259 A JP2023502259 A JP 2023502259A JP 2022529298 A JP2022529298 A JP 2022529298A JP 2022529298 A JP2022529298 A JP 2022529298A JP 2023502259 A JP2023502259 A JP 2023502259A
Authority
JP
Japan
Prior art keywords
cela1
residues
lung
human
emphysema
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022529298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502259A5 (enExample
Inventor
バリスコ、ブライアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center filed Critical Cincinnati Childrens Hospital Medical Center
Publication of JP2023502259A publication Critical patent/JP2023502259A/ja
Publication of JP2023502259A5 publication Critical patent/JP2023502259A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21036—Pancreatic elastase (3.4.21.36)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022529298A 2019-11-26 2020-11-23 肺疾患の治療のためのｃｅｌａ－１阻害 Pending JP2023502259A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962940302P 2019-11-26 2019-11-26
US62/940,302 2019-11-26
US202063009134P 2020-04-13 2020-04-13
US63/009,134 2020-04-13
PCT/US2020/061774 WO2021108302A1 (en) 2019-11-26 2020-11-23 Cela-1 inhibition for treatment of lung disease

Publications (2)

Publication Number Publication Date
JP2023502259A true JP2023502259A (ja) 2023-01-23
JP2023502259A5 JP2023502259A5 (enExample) 2023-10-24

Family

ID=76129647

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022529298A Pending JP2023502259A (ja) 2019-11-26 2020-11-23 肺疾患の治療のためのｃｅｌａ－１阻害

Country Status (6)

Country Link
US (1) US20230002510A1 (enExample)
EP (1) EP4065167A4 (enExample)
JP (1) JP2023502259A (enExample)
AU (1) AU2020394374A1 (enExample)
IL (1) IL293238A (enExample)
WO (1) WO2021108302A1 (enExample)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130052258A1 (en) * 2009-09-22 2013-02-28 Xmedic Ab Polypeptides and uses thereof
US20150140609A1 (en) * 2002-03-13 2015-05-21 Biogen Idec Ma Inc. Anti-alpha(v)beta(6) Antibodies
US20180312477A1 (en) * 2015-04-07 2018-11-01 Ela Pharma Ltd Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
WO2019140380A1 (en) * 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501449B2 (en) * 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150140609A1 (en) * 2002-03-13 2015-05-21 Biogen Idec Ma Inc. Anti-alpha(v)beta(6) Antibodies
US20130052258A1 (en) * 2009-09-22 2013-02-28 Xmedic Ab Polypeptides and uses thereof
US20180312477A1 (en) * 2015-04-07 2018-11-01 Ela Pharma Ltd Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
WO2019140380A1 (en) * 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AM. J. RESPIR. CELL MOL. BIOL., vol. 59, no. 2, JPN6024039974, 2018, pages 167 - 178, ISSN: 0005781095 *
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. Vol.199, No.9, Abstract No. A5365, JPN6024039973, May 2019 (2019-05-01), ISSN: 0005781096 *

Also Published As

Publication number Publication date
US20230002510A1 (en) 2023-01-05
IL293238A (en) 2022-07-01
WO2021108302A1 (en) 2021-06-03
EP4065167A4 (en) 2024-03-27
AU2020394374A9 (en) 2022-06-16
EP4065167A1 (en) 2022-10-05
AU2020394374A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
AU2022221419B2 (en) Methods for inhibiting fibrosis in a subject in need thereof
JP2020504076A (ja) 抗ｔｌ１ａモノクローナル抗体の中和
US20230212276A1 (en) Monoclonal antibody and antigens for diagnosing and treating lung disease and injury
WO2018017443A1 (en) Immunogenic compositions and methods relating thereto
EA035223B1 (ru) Способ лечения немелкоклеточного рака легкого
EP2421562A1 (en) Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US10633455B2 (en) Method for treating and diagnosing disease using inhibitors of goodpasture antigen binding protein
US20170080053A1 (en) Regulation of sodium channels by plunc proteins
JP2017186340A (ja) 血液凝固促進に使用するための化合物
WO2014089267A1 (en) Galectin-3 fusion proteins
TW202402790A (zh) 減少呼吸系統感染之方法
CN105873950A (zh) 用于治疗和诊断癌症的抗s100a7抗体
JP2009505979A (ja) アルツハイマー病の治療に使用するためのトランケート型メマプシン２
WO2020096046A1 (ja) 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン
US20230002510A1 (en) Cela-1 inhibition for treatment of lung disease
WO2021205150A1 (en) An enzyme
US20190352368A1 (en) Identification of novel anti-fibrotic peptide in c-terminal region of the met receptor tyrosine kinase
CN102131547A (zh) Sparc抗炎活性及其用途
WO2016005545A1 (en) Substances and methods for the use in prevention and/or treatment in huntington's disease
KR20220159053A (ko) Ncapg2의 1010번째 트레오닌의 인산화 특이적 반응 여부를 확인하기 위한 항체 및 이의 이용
Hu et al. CXCR4 inhibition alleviates prostatic inflammation and pelvic pain via suppressing Th17 cell differentiation and oxidative stress in EAP mice
CN119841942B (zh) 一种抗igfbp5纳米抗体及其制备方法、应用和产品
CN113398270B (zh) 一种治疗骨巨细胞瘤的方法
DK2691526T3 (en) COMPOSITIONS FOR USE IN TREATMENT AND PROCEDURES FOR DIAGNOSIS AND CANCER MONITORING
WO2006106599A1 (ja) 細胞外ドメインシェディングの異常亢進に起因する疾患の予防及び／又は治療のための医薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260127